DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/htm99h/lung_cancer) has announced the addition of the "Lung Cancer Pipeline Highlights - 2015" report to their offering.
The latest report Lung cancer Pipeline Highlights - 2015, provides most up-to-date information on key pipeline molecules in the global Lung cancer market. It covers emerging therapies for Lung cancer in active clinical development stages including early and late stage clinical trials. The pipeline data presented in this report helps executives for tracking competition, identifying partners, evaluating opportunities, formulating business development strategies, and executing in-licensing and out-licensing deals.
Clinical Trial Stages:
The report provides Lung cancer pipeline molecules by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.
Drug Mechanism Classes:
The report provides Lung cancer pipeline molecules by their dominant mechanism of action. This helps executives categorize molecules based on their drug class and also assess the strengths and weaknesses of compounds.
The report provides Lung cancer pipeline molecules by the Originator Company.
Short-term Launch Highlights:
Find out which Lung cancer pipeline products will be launched in the US and Ex-US till 2017.
Key Topics Covered:
1. Lung cancer Pipeline by Stages
2. Lung cancer Pipeline by Drug Class
3. Lung cancer Pipeline by Company
4. Lung cancer Phase 3 Clinical Trial Insights
5. Lung cancer Phase 2 Clinical Trial Insights
6. Lung cancer Phase 1 Clinical Trial Insights
7. Lung cancer Preclinical Research Insights
8. Lung cancer Discovery Stage Insights
10. Research Methodology
For more information visit http://www.researchandmarkets.com/research/htm99h/lung_cancer